A recent decision passed by the Delhi High Court on 20 August
held that infringement actions cannot be maintained when the
patent-in-suit is revoked, regardless of whether the revocation is
being appealed. As a result, the court cancelled an interim
injunction it had previously imposed on an alleged infringer prior
to the revocation of the patent it was deemed to infringe.
The decision relates to a suit filed by Novartis AG against
Natco Pharma [CS (Comm.) 229 of 2019], in which the plaintiff
sought a permanent injunction, damages and rendition of accounts to
remedy the alleged infringement of patent IN276026 ('026).
Granted on 28 September 2016, this patent covers the active
pharmaceutical ingredient ceritinib intended for the treatment of
non-small cell lung cancer.